PIOGLITAZONE 15mg. IP

An anti-hyperglycemic agent that is primarily used for the management of type 2 diabetes mellitus. An oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver, and muscles. (Pablos-Velasco, 2010) Improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. (Pablos-Velasco, 2010) Effectively improves blood glucose levels, long-term glucose control, and the lipid profile in patients with type 2 diabetes mellitus. (Andreas Pfützner, 2006) An attractive and effective treatment option for managing type 2 diabetes mellitus. (Andreas Pfützner, 2006) Significantly improves HbA1c and FPG while producing beneficial effects on serum lipids in patients with type 2 diabetes. (S Aronoff, 2000) Exerts additional beneficial vascular effects in patients with type 2 diabetes mellitus. (Keiichiro Harashima, 2009) A well-tolerated agent in patients with varying degrees of renal impairment. (Klemens Budde, 2003) Improves insulin resistance in Type 2 diabetes without inducing insulin secretion from pancreatic β-cells, thereby reducing the risk of hypoglycemia. (Klemens Budde, 2003) Controls blood sugar levels by increasing the body's sensitivity to insulin, a hormone that regulates glucose metabolism. Ameliorates glycaemic control, by lowering fasting and postprandial blood glucose levels, and improves insulin sensitivity. (Michaela Diamant, 2003) Alleviates insulin resistance associated with type 2 diabetes and improves hyperglycemia, reducing HbA1c levels. (Toyota, 2001) Offers an effective approach to reducing measures of cardiovascular risk and arteriosclerosis. (John Waugh, 2006) A more beneficial treatment option for managing coronary artery disease progression in individuals with type 2 diabetes. (Steven E Nissen & Investigators, 2008)